Cancer researchers may finally have viable strategies to attack one of oncology's most elusive targets. The MYC oncoprotein drives tumor growth in over 70% of human cancers, yet its disordered structure and nuclear location have earned it the dreaded 'undruggable' designation that has stymied therapeutic development for decades.
This comprehensive analysis of small-molecule inhibitors identifies two distinct mechanisms that successfully disrupt MYC function. The first approach breaks apart the critical MYC-MAX protein partnership that enables cancer cell proliferation. The second stabilizes G-quadruplex DNA structures in the MYC gene promoter, effectively silencing MYC production at its source. Multiple chemical scaffolds show promise, including indenoisoquinoline and dibenzoquinoxaline derivatives, each exploiting specific molecular features like planar aromatic cores for optimal protein binding.
The structure-activity insights represent a significant advance in precision drug design for cancer. Previous attempts to target MYC failed largely because researchers lacked detailed understanding of which molecular features drive effectiveness. This systematic mapping of chemical structure to biological activity across multiple inhibitor classes provides the blueprint needed for rational drug development. While these compounds remain in early research phases, the dual-pathway approach suggests MYC may not be undruggable after all. The findings could accelerate development of therapies for notoriously difficult cancers where MYC drives resistance to conventional treatments, potentially opening new treatment avenues for patients with limited options.